Uncategorized
Where CVS Health Stands With Analysts
Latest Ratings for CVS Date Firm Action From To Feb 2022 Raymond James Downgrades Strong Buy Outperform Dec 2021 Tigress Financial Maintains Buy Dec 2021 Mizuho Maintains Buy View More Analyst Ratings for CVS View the Latest Analyst Ratings read more
Beyond The Numbers: 10 Analysts Discuss Biogen Stock
Latest Ratings for BIIB Date Firm Action From To Mar 2022 Stifel Downgrades Buy Hold Mar 2022 RBC Capital Upgrades Sector Perform Outperform Feb 2022 Canaccord Genuity Maintains Buy View More Analyst Ratings for BIIB View the Latest Analyst Ratings read more
REV Group Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Latest Ratings for REVG Date Firm Action From To Mar 2022 Credit Suisse Maintains Underperform Dec 2021 Credit Suisse Maintains Underperform Dec 2021 Goldman Sachs Maintains Sell View More Analyst Ratings for REVG View the Latest Analyst Ratings read more
Joby’s 38% Stock Plunge Is Ugly—But The Pentagon Might Be Interested
Defense contracts could provide Joby with near-term funding to navigate turbulent financial waters as it works toward commercial revenue. read more
FDA Confirms Direct Review Path For Aquestive’s Allergy Treatment
Aquestive’s Anaphylm could become the first oral epinephrine for severe allergic reactions after the FDA set a 2026 decision date without panel review. Latest Ratings for AQST Date Firm Action From To Sep 2020 RBC Capital Maintains Outperform Sep 2020 HC Wainwright & Co. Maintains Buy May 2020 HC Wainwright & Co. Maintains Buy View…
Weak Jobs Cement Fed Rate Cuts–And Wall Street Eyes Records Again
Markets re-enter bad-news-is-good-news mode as weak jobs data boosts bets on Fed rate cuts. S&P 500 nears record high. read more
